147 related articles for article (PubMed ID: 14645425)
1. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC
J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425
[TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Kohn EC; Reed E; Sarosy G; Christian M; Link CJ; Cole K; Figg WD; Davis PA; Jacob J; Goldspiel B; Liotta LA
Cancer Res; 1996 Feb; 56(3):569-73. PubMed ID: 8564973
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
Bhoola SM; Coleman RL; Herzog T; Morris R; Bryant C; Estes JM; Alvarez RD
Gynecol Oncol; 2004 Dec; 95(3):564-9. PubMed ID: 15581964
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Bauer KS; Figg WD; Hamilton JM; Jones EC; Premkumar A; Steinberg SM; Dyer V; Linehan WM; Pluda JM; Reed E
Clin Cancer Res; 1999 Sep; 5(9):2324-9. PubMed ID: 10499600
[TBL] [Abstract][Full Text] [Related]
13. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Smyth JF; Gourley C; Walker G; MacKean MJ; Stevenson A; Williams AR; Nafussi AA; Rye T; Rye R; Stewart M; McCurdy J; Mano M; Reed N; McMahon T; Vasey P; Gabra H; Langdon SP
Clin Cancer Res; 2007 Jun; 13(12):3617-22. PubMed ID: 17575226
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
Alvarez Secord A; Jones EL; Hahn CA; Petros WP; Yu D; Havrilesky LJ; Soper JT; Berchuck A; Spasojevic I; Clarke-Pearson DL; Prosnitz LR; Dewhirst MW
Int J Hyperthermia; 2005 Jun; 21(4):333-47. PubMed ID: 16019859
[TBL] [Abstract][Full Text] [Related]
17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
18. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
